Ntla stock forecast.

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.41. This compares to loss of $1.96 per share a year ago.Jun 13, 2023 · Intellia's Q1 2023 financial report shows a cash position of $1.2 billion, with collaboration revenue rising to $12.6 million and a net loss of $103.1 million. The success of NTLA-2002 in further ... Intellia Therapeutics has recently been granted FDA clearance to include the United States in the global Phase 2 portion of its Phase 1/2 study for NTLA-2002. This is a significant milestone for ...Dec 1, 2023 · NTLA is a biotech company that develops gene editing therapies for cancer and other diseases. The average price target for its stock is $82.19, with a range of $40 to $144, based on 21 analyst recommendations. The stock has a strong buy rating from 18 brokerage firms and a low of 40.00. The upside is 237.12%.

The stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days ...

Stock Price Forecast The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00.Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...

NTLA stock forecast for 2023 – 2027. Last updated: November 23, 2023. NTLA. Intellia Therapeutics, Inc. 30.26 D 6.32% (1.80) Are you interested in Intellia Therapeutics, Inc. stocks prediction?Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceOn today's stock market, NTLA stock skidded 3.8%, reversing from a premarket climb and closing at 27.96. Shares of Regeneron Pharmaceuticals ( REGN ), which is collaborating with Intellia on the ...There was a snowstorm in the Northeast this week. Or maybe that supposed storm was just a light dusting. It depends on who you ask. Having grown up in the mountains of Colorado, I am well aware at just how terrible these forecasts tend to b...

EXEL : EXELIXIS INC stock forecast by Wall Street Analysts. The average EXELIXIS INC stock forecast from last 6 month is $25.28, and this show a 7.89% increase in average from the prior price target of the each prediction. Also, this average forecast of $25.28 represents a 1.73% increase from the past average forecast of $24.85, 6 months ago from 13 wall …

The Intellia Therapeutics stock forecast for tomorrow is $ 24.26, which would represent a 1.07% gain compared to the current price. In the next week, the price of NTLA is expected to increase by 5.31% and hit $ 25.28. As far as the long-term Intellia Therapeutics stock forecast is concerned ...

Stock Price Forecast. According to 20 stock analysts, the average 12-month stock price forecast for NTLA stock stock is $77.4, which predicts an increase …4 Growth Stocks, 4 Value Stocks to Buy Each stock offers a different opportunity in this uncertain market outlook. Jeff Reeves and Jordan Schultz Nov. 27, 2023Nov 23, 2023 · NTLA stock forecast for 2023 – 2027. Last updated: November 23, 2023. NTLA. Intellia Therapeutics, Inc. 30.26 D 6.32% (1.80) Are you interested in Intellia Therapeutics, Inc. stocks prediction? Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business.NTLA stock's Price/Earning ratio is 115.00. Our analysis grades NTLA stock's Price / Earning ratio at F. This means that NTLA stock's Price/Earning ratio is above 92% of the stocks in the Biotechnology sector in the NSD exchange. Based on this NTLA may be a overvalued for its sector.Price Target Based on short-term price targets offered by 21 analysts, the average price target for Intellia Therapeutics, Inc. comes to $77.52. The forecasts range …Stock Price Forecast. The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00. The median estimate represents a +175.23% increase from the last price of 26.16.

Nov 24, 2023 · The Intellia Therapeutics Inc stock price gained 2.54% on the last trading day (Friday, 24th Nov 2023), rising from $30.26 to $31.03. During the last trading day the stock fluctuated 5.87% from a day low at $30.13 to a day high of $31.90. The price has risen in 6 of the last 10 days and is up by 24.32% over the past 2 weeks. Jun 8, 2023 · Here, I discuss the central investing thesis for its fellow CRISPR/Cas9 gene-editing specialist, Intellia Therapeutics (NTLA 2.54%). This biotech growth stock, too, stands out as a potential ... Get The Latest QCOM Stock Analysis, Price Target, Dividend Info, Headlines, Short Interest at MarketBeat. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. ... Being profitable and raising its production forecast are two reasons the Chinese EV maker Li Auto distinctly stands out from its peers Nio and Xpeng. November 13, 2023 | marketbeat ...The average Intellia Therapeutics stock price prediction forecasts a potential upside of 203.75% from the current NTLA share price of $25.50. What is NTLA's forecast return on assets (ROA) for 2023-2026? Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating …

Jun 23, 2023 · This stock has a credible chance of climbing, if not soaring. ... In the same period, the company plans to submit an IND for NTLA-3001, its therapy for alpha-1 antitrypsin deficiency-related lung ... Intellia Therapeutic’s stock (NASDAQ NDAQ +3.2%: NTLA), a biotechnology company developing treatments using the CRISPR gene-editing system, has seen a fall of 31% in a month, while it’s down ...

Do you wonder where the stock market is headed? Well, Wells Fargo’s senior global market strategist, Scott Wren, believes that the S&P 500 will remain range-bound, with a low end around 3,600 and a top end around 4,300, for the remainder of the year. Wren’s advice is not to chase the market when it nears that peak, but to make use …Caribou Biosciences, Inc. 5.69. +0.39. +7.36%. In this article, we discuss 10 best gene editing stocks to buy. If you want to see more stocks in this selection, check out 5 Best Gene Editing ...The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is anticipated to initiate by year-end 2023. "The FDA clearance of the NTLA-2001 IND application allows us to initiate a pivotal Phase 3 trial in the United States, marking the first in vivo CRISPR-based candidate to begin late-stage clinical development.What this means: InvestorsObserver gives Intellia Therapeutics Inc. (NTLA) an overall rank of 36, which is below average. Intellia Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 36 means that 64% of stocks appear more favorable to our system.Intellia Therapeutics (NTLA) Stock Forecast & Price Prediction. Estimation of the future price movement of Intellia Therapeutics stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.Nov 30, 2023 · According to 2 stock analysts, the average 12-month stock price forecast for DNA stock stock is $1.88, which predicts an increase of 45.74%. The lowest target is $1.25 and the highest is $2.50. On average, analysts rate DNA stock stock as a sell. The current Intellia Therapeutics [ NTLA] share price is $28.76. The Score for NTLA is 45, which is 10% below its historic median score of 50, and infers higher risk than normal. NTLA is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. Jul 6, 2023 · Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Sumitomo Mitsui Trust Holdings ( OTC: CMTDF) has acquired additional shares in Intellia Therapeutics ( NSD:NTLA) during the fourth quarter, according to the company’s latest filing with the Securities and Exchange Commission. The investor now owns 2,976,002 shares, an increase of 0.4% or 12,074 shares. The stake is valued at …

Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: These 12 analysts have an average price target of $77.5 versus the current price of Intellia ...

The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00. The median estimate represents a +137.08% increase from the last price of 30.37. The current consensus among 27 polled investment analysts is to Buy stock in Intellia ...

Find real-time GILD - Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN Business.Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing ...The stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days ...About the Vertex Pharmaceuticals, Inc. stock forecast. As of 2023 December 03, Sunday current price of VRTX stock is 351.160$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Vertex Pharmaceuticals stock price as been showing a rising tendency so we believe that …Intellia Therapeutics (NTLA 2.54%) works in the up-and-coming area of gene editing. Invitae ( NVTA -0.52% ) specializes in genetic testing. Both stocks have declined over the past year.Intellia's Q1 2023 financial report shows a cash position of $1.2 billion, with collaboration revenue rising to $12.6 million and a net loss of $103.1 million. The success of NTLA-2002 in further ...Analysts rate Intellia Therapeutics Inc. with a consensus Strong Buy rating with an average 12-months Intellia stock price target of $166.36 per sharePeople use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.Future criteria checks 2/6. Intellia Therapeutics is forecast to grow earnings and revenue by 6.3% and 57.2% per annum respectively. EPS is expected to grow by 11.3% per annum. Return on equity is forecast to be -20.1% in 3 years.It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...

Intellia was founded in 2014 and went public in 2016, raising net proceeds of $112.1 million at $18 per share. The stock currently trades around $36.00 a share, translating to a market cap of $3. ...Jun 8, 2023 · Here, I discuss the central investing thesis for its fellow CRISPR/Cas9 gene-editing specialist, Intellia Therapeutics (NTLA 2.54%). This biotech growth stock, too, stands out as a potential ... Intellia Therapeutics Stock Forecast and Price Target 2023 (NASDAQ:NTLA) Headlines About NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock …Instagram:https://instagram. 1964 half dollar silver valuemilwaukee stocktradovate trialbest real estate crowdfunding platforms A high-level overview of Intellia Therapeutics, Inc. (NTLA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. nasdaq avtxconstallation brands Stock Price Forecast. The 33 analysts offering 12-month price forecasts for Mastercard Inc have a median target of 440.00, with a high estimate of 484.00 and a low estimate of 410.00. The median estimate represents a +6.67% increase from the last price of 412.48. nasdaq zyne Discover historical prices for NTLA stock on Yahoo Finance. View daily, weekly or monthly format back to when Intellia Therapeutics, Inc. stock was issued. Intellia Therapeutics Inc’s Stock Price as of Market Close. As of March 22, 2023, 4:00 PM CST, Intellia Therapeutics Inc’s stock price was $37.15. Intellia Therapeutics Inc is down 6.63% from its previous closing price of $39.79. During the last market session, Intellia Therapeutics Inc’s stock traded between $38.25 and $39.94.Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance